STOCKSCREENR

LLY vs NVO

Comparing Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) across valuation, profitability, financial health, growth, performance, and analyst metrics. Both companies operate in the Healthcare sector.

Price & Valuation

LLY
Metric
NVO
$976.45
Price
$38.13
$921.14B
Market Cap
$169.45B
42.45
P/E Ratio
10.65
33.51
P/B Ratio
5.68
14.33
P/S Ratio
3.56
3.53
PEG Ratio
-8.66
0.00
EV/EBITDA
43.17

Profitability

LLY
Metric
NVO
$23.00
EPS
$3.58
+0.98%
ROE (TTM)
+0.61%
+0.18%
ROA (TTM)
+0.19%
+0.84%
Gross Margin
+0.81%
+0.46%
Operating Margin
+0.41%
+0.34%
Net Margin
+0.34%

Financial Health

LLY
Metric
NVO
1.60
Debt/Equity
0.67
1.58
Current Ratio
0.80
0.43
Beta
0.27

Dividends

LLY
Metric
NVO
Dividend Yield
+0.20%
Payout Ratio
+0.00%

Growth

LLY
Metric
NVO
+0.50%
EPS Growth (YoY)
-0.05%
+0.42%
Revenue Growth (YoY)
-0.07%

Performance

LLY
Metric
NVO
-1.92%
1 Day
-0.51%
-3.67%
1 Month
-16.48%
-5.16%
YTD
-6.24%
1 Year

Analyst

LLY
Metric
NVO
1.50
Analyst Score
2.00
$1212.18
Target Consensus
$47.00

This side-by-side comparison of Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) covers key financial metrics including valuation ratios, profitability margins, balance sheet strength, dividend yields, growth rates, price performance, and analyst consensus. Green-highlighted values indicate the "winner" for each metric — higher is better for profitability and growth metrics, while lower is better for valuation and risk metrics. Use the free stock screener to compare any stocks across dozens of fundamental and technical filters.